Ratio Therapeutics, a Boston, MA-based pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, raised $20M in Series A funding.
The round was led by Duquesne Capital and Schusterman Family Investments. Kenan Turnacioglu, Ph.D., General Partner at Catalio Capital Management, will representing them, joining as an executive advisor. Ratio also added Susan K. Whoriskey, Ph.D., to its board of directors as a strategic advisor who will work closely with the executive team at Ratio to implement strategies for translating scientific advancements into approved therapies.
The company intends to use the funds to optimize and expand the breadth of its proprietary Trillium and Macropa technology platforms, accelerate the discovery and development of targeted radiotherapies and diagnostics leveraging the platforms’ tunable nature to advance programs through clinical-stage development as well as expand the team through hiring and forming new strategic partnerships.
Founded by John Babich, Ph.D., and Jack Hoppin, Ph.D., Ratio Therapeutics is a pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. The company currently employs a team of radiopharmaceuticals discovery and development experts with backgrounds in the life science industry. Its proprietary R&D platforms, Trillium and Macropa, enable the imaging, discovery, and advancement of novel radiopharmaceuticals.
Ratio currently collaborates with Bayer and Lantheus.
FinSMEs
01/02/2023